Carcinoma in Situ of the Bladder
📧 Sign up to get email alerts when something new happens for Carcinoma in Situ of the Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer [Phase 3]
Phase 3 trial evaluating intravesical nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy for high-grade BCG…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC [Phase 2]
Phase 2 clinical trial evaluating intravesical gemcitabine and docetaxel for high-risk, BCG-unresponsive non-muscle-invasive bladder cancer;…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer [Phase 2]
A Phase 2 study is testing pembrolizumab added to intravesical gemcitabine for BCG-unresponsive non-muscle invasive bladder cancer, with the…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) [Phase 2]
A Phase 2 study of Intismeran Autogene (V940) in combination with BCG for bladder cancer is currently recruiting, targeting non-muscle-invas…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial [Phase 1, Phase 2]
The INVITE trial is investigating in-home intravesical chemotherapy for non-muscle invasive bladder cancer and is currently recruiting for P…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer [Phase 3]
Phase 3 trial update assessing intravesical TARA-002 versus investigator's choice intravesical chemotherapy for BCG-naïve high-grade non-mus…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve [Phase 1, Phase 2]
A Phase 1/2 study (LEGEND Study: EG-70) is recruiting to evaluate EG-70 in non-muscle invasive bladder cancer, including patients with carci…
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 1]
A Phase 1 dose-escalation study of UGN-301 in patients with recurrent non-muscle invasive bladder cancer has been completed.
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients [NA]
A clinical trial update describing Hyperthermic Intravesical Chemotherapy (HIVEC) for high-grade non-muscle invasive bladder cancer that is …
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 1]
A Phase 1 trial of intravesical Enfortumab Vedotin for non-muscle invasive bladder cancer was terminated, with the study status updated acco…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study [Phase 2]
This update describes an open-label, randomized Phase 2 trial evaluating toripalimab with or without sequential intravesical gemcitabine-mit…
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder [Phase 2]
Phase 2 trial of durvalumab (Medi4736) for BCG-refractory urothelial carcinoma in situ of the bladder (terminated; results posted).
-
FDA approval · 2019-04-19FDA Approved: VALRUBICIN INTRAVESICAL SOLUTION — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma's generic valrubicin intravesical solution (ANDA 206430) for carcinoma in situ of the bladder in patients who have failed…
-
CLINICAL_TRIALS trial_result · 2018-03-13Clinical Trial Update: RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder [Phase 1, Phase 2]
This phase 1/2 trial evaluated intravesical gemcitabine in combination with RAD001 (everolimus) for BCG-refractory carcinoma in situ of the …
-
CLINICAL_TRIALS trial_result · 2015-06-12Clinical Trial Update: Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) [Phase 2, Phase 3]
The document reports the completion status of a Phase 2/3 clinical trial evaluating intravesical valrubicin (AD 32) for carcinoma in situ of…
-
CLINICAL_TRIALS trial_result · 2015-02-10Clinical Trial Update: Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer [Phase 2]
Phase 2 study evaluating TMX-101 for carcinoma in situ of the bladder and non-muscle-invasive bladder cancer has completed.
-
CLINICAL_TRIALS trial_result · 2014-10-22Clinical Trial Update: Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder [Phase 3]
A Phase 3 trial evaluating maintenance valrubicin versus no maintenance after valrubicin induction in bladder carcinoma in situ; study termi…
-
CLINICAL_TRIALS trial_result · 2014-02-19Clinical Trial Update: Retrospective Chart Review of Valstar
A completed retrospective chart review of Valstar for carcinoma in situ of the bladder.
-
FDA approval · 2013-11-12FDA Approved: VALSTAR — Supplemental Application (Endo USA, Inc.)
The FDA approved a supplemental application for VALSTAR (valrubicin) submitted by Endo USA, Inc.
-
FDA approval · 2012-12-20FDA Approved: VALSTAR — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for VALSTAR (valrubicin) from Endo USA, Inc., supporting updated labeling and/or indications for int…